Oncology

To promote collaboration and efficiency, the MD Anderson Cancer Center developed an interdisciplinary team—based Heart Success Program to coordinate the management of concurrent cardiomyopathy and HF while the patient is receiving cancer treatment.

Steve Miller, MD, chief medical officer of Express Scripts, explained indication-specific pricing as an alternate pricing model for high cost specialty medications like oncology drugs.

A patient advocate underscores the need for awareness and self-advocacy among cancer patients by highlighting her own experience as a survivor, who experienced delayed cardiotoxic effects of chemotherapy.

With the prognosis for many cancers improving, we are seeing an appropriate sharpening of focus on the cardiovascular risks of patients who have survived cancer or are being treated for cancer, as well as a growing recognition of the impact this competing morbidity has on both short- and long-term health outcomes.

With the explosion of new therapies in cancer care, the risk of each new therapy must be clearly understood prior to making treatment decisions with patients. Data from clinical trials alone are insufficient to educate these treatment choices, and real-world evidence from higher-risk populations should be generated to inform these treatment decisions.

A study published in Nature Medicine highlights how genetic data can be translated in disease prevention and evidence-based clinical management.

ASCO says that it's Patient-Centered Oncology Payment model meets the criteria for an Alternative Payment Model as defined by Congress in the Medicare Access and CHIP Reauthorization Act of 2015, which replaced the Sustainable Growth Rate formula.